다른 뉴스레터 둘러보기
FDA 자료 Presenting Quantitative Efficacy and Risk Information in Direct-to-Consumer Promotional Labeling and Advertisements Guidance for Industry | Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings Guidance for Industry [PDF 다운]
FDA, 셀트리온 트룩시마 긍정 평가…승인 가능성은 | [초점]간세포암 1차 치료에서의 '렌비마' 등장, 그 의미와 쟁점 | 다국적사 잇단 계약직 해지통보…파이프라인 부재 원인
FDA 자료 Product-Specific Guidances for Generic Drug Development | FDA updates on valsartan recalls [클릭] Impact Story: Evaluating the Potential of Microengineered Human Cellular Systems to Predict Drug Effects in the Clinic [클릭]
'박사급 인력' 모시기 분주한 바이오벤처들 | GC녹십자, 만성 B형 간염 완치 앞장 | 사노피, 6번째 면역관문억제제 '리브타요' FDA 허가
FDA 자료 Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use Guidance for Industry | Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry (PDF - 195KB)